Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Sutro Biopharma (STRO) Receivables - Other (2017 - 2020)

Sutro Biopharma's Receivables - Other history spans 4 years, with the latest figure at $6.4 million for Q1 2020.

  • For Q1 2020, Receivables - Other rose 439.06% year-over-year to $6.4 million; the TTM value through Mar 2020 reached $6.4 million, up 439.06%, while the annual FY2019 figure was $1.0 million, 9.49% up from the prior year.
  • Receivables - Other for Q1 2020 was $6.4 million at Sutro Biopharma, up from $1.0 million in the prior quarter.
  • Across five years, Receivables - Other topped out at $6.4 million in Q1 2020 and bottomed at $784000.0 in Q4 2017.
  • The 4-year median for Receivables - Other is $1.1 million (2019), against an average of $1.9 million.
  • The largest annual shift saw Receivables - Other grew 9.49% in 2019 before it skyrocketed 439.06% in 2020.
  • A 4-year view of Receivables - Other shows it stood at $784000.0 in 2017, then rose by 22.32% to $959000.0 in 2018, then increased by 9.49% to $1.0 million in 2019, then skyrocketed by 509.9% to $6.4 million in 2020.
  • Per Business Quant, the three most recent readings for STRO's Receivables - Other are $6.4 million (Q1 2020), $1.0 million (Q4 2019), and $2.1 million (Q3 2019).